PortfoliosLab logo
Adaptimmune Therapeutics plc (ADAP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00653A1079

CUSIP

00653A107

IPO Date

May 6, 2015

Highlights

Market Cap

$77.22M

EPS (TTM)

-$0.30

PEG Ratio

0.11

Total Revenue (TTM)

$172.35M

Gross Profit (TTM)

$166.84M

EBITDA (TTM)

-$9.82M

Year Range

$0.29 - $0.32

Target Price

$1.71

Short %

2.04%

Short Ratio

2.60

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ADAP vs. SCHD
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period


ADAP

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.77%

1M

5.53%

6M

-5.60%

1Y

8.37%

5Y*

14.61%

10Y*

10.35%

*Annualized

Monthly Returns

The table below presents the monthly returns of ADAP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-3.34%-3.34%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ADAP is 8, meaning it’s performing worse than 92% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ADAP is 88
Overall Rank
The Sharpe Ratio Rank of ADAP is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of ADAP is 88
Sortino Ratio Rank
The Omega Ratio Rank of ADAP is 99
Omega Ratio Rank
The Calmar Ratio Rank of ADAP is 77
Calmar Ratio Rank
The Martin Ratio Rank of ADAP is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Adaptimmune Therapeutics plc (ADAP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Adaptimmune Therapeutics plc. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


Adaptimmune Therapeutics plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Adaptimmune Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adaptimmune Therapeutics plc was 3.34%, occurring on May 9, 2025. The portfolio has not yet recovered.

The current Adaptimmune Therapeutics plc drawdown is 3.34%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-3.34%May 6, 20254May 9, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Adaptimmune Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Adaptimmune Therapeutics plc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -55.5%.


-0.30-0.20-0.100.000.100.20AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
-0.24
-0.15
Actual
Estimate

Valuation

The Valuation section provides an overview of how Adaptimmune Therapeutics plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ADAP compared to other companies in the Biotechnology industry. ADAP currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ADAP relative to other companies in the Biotechnology industry. Currently, ADAP has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ADAP in comparison with other companies in the Biotechnology industry. Currently, ADAP has a P/B value of 6.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items